The global sleep aids market size accounted for USD 74.3 billion in 2021 and is expected to hit around USD 124.97 billion by 2030, poised to grow at a CAGR of 5.95% from 2022 to 2030.
Key Takeaways:
- The sleep laboratories segment is expected to grow at a CAGR of 8.3% from 2022 to 2030.
- The restless legs syndrome segment is predicted to grow at a CAGR of 8.1% from 2022 to 2030.
- Asia-Pacific region is anticipated to reach at a CAGR of 9.4% over the forecast timeframe from 2022 to 2030.
The main biological need is Sleep which helps in influencing memory, keeping cognitive functions, and metabolic homeostasis. The overall health of humans is affected due to negative sleeping conditions which lead to long-lasting or chronic diseases like diabetes, arthritis, high blood pressure, and stroke. Their supports are drugs and medical devices which are used for treating & diagnosing different forms of sleep conditions, like insomnia, narcolepsy, sleep apnea, and others. The increasing effort of the worldwide population on the antagonistic effects of this condition is expected to drive the evolution of the market for sleeping aids.
The absence of appropriate documents for the permitting license and use of pills or medicines and the inappropriate calibration of devices of sleeping aids is predicted to undesirable impact on the industry of sleeping aids. Though, the increasing difficulty and anxieties in sleeping disorder treatment owed to the introduction of the latest technologies are likely to hamper the progress of the market of sleeping aids.
Sleep Aids Market Scope
| Report Coverage | Details |
| Market Size in 2022 | USD 78.72 Billion |
| Market Size by 2030 | USD 124.97 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 5.95% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Product, Sleep-Disorder, Geography |
| Companies Mentioned | Acelity L.P. Inc. (Kinetic Concepts, Inc.), AstraZeneca Plc, Biodiem, Cadwell Industries Inc., Compumedics Limited, CSL Limited, Drive, Drive DeVilbiss Healthcare Inc., Eisai Co., Ltd., Emergent Biosolutions, F.Hoffmann-La Roche Ltd., Fisher & Paykel Healthcare Limited, Gamma Vaccines Pty Ltd., GlaxoSmithKline Plc., Koninklijke Philips N.V., Merck and Co. Inc., Natus Medical Incorporated, Novartis AG, Pfizer Inc., ResMed Inc., Sanofi S.A., Serta Simmons Bedding LLC, Sinovac Biotech Ltd., SleepMed Inc., Takeda Pharmaceutical Company Limited, Tempur Sealy International Inc. |
Report Highlights
- Growing consumer non-refundable income, shared with increasing public awareness of the sleep disorders’ antagonistic effects can grow the market size of sleeping aids during the expected period. Also, sleeping aid like diabetes, arthritis, high blood pressure, and stroke, may badly disturb human health which leads to chronic diseases.
- Increasing incidence of sleep disorders like disruptive sleep apnoea, chronic insomnia, and narcolepsy will also help in growing the business in the upcoming years with worldwide sleep aids devices. These factors will deliver profitable development for the growth of the market of sleep aids in the upcoming years.
Market Dynamics
Drivers
- The main factor driving the development of the market for sleeping aids is the altering sleep form of the worldwide population caused by altering lifestyles. Additionally, the growing wealth of the consumers attached with the better contact with medical facilities on account of the increasing claim for worth health care is predicted to grow the market.
- Increasing sanctions of new product development in the market and growing government capital for research & development (R&D) are projected to bid huge sleep aids business development opportunities. Increasing occurrence of sleeping conditions like disruptive sleep apnea, chronic insomnia, and narcolepsy may excite sleep change. Sleep aids are complicated in OSA treatment and insomnia which helps in increasing the development of the worldwide market of sleep aids.
- The growing M&A (Merger & Acquisition) between industry players to increase their geographic occurrence and product collection is expected to initiate market growth. Another key feature of sleeping aids is the growing acceptance of wearable sensors and tracking devices. Sensor-equipped systems make diverse motives like evaluating the excellence of sleep and chasing sleep illnesses.
- The machines record and allocate data regarding diverse physical situations. The lifestyle variations and tense working atmospheres affect sleep patterns, vital to changing sleep disorders. This performance is an important driving force in the upcoming years and will excite the growth of universal sleep aids occupational.
Restraints
The introduction of innovative technologies has increased difficulty in the treatment of sleeping aids conditions. Also, the absence of appropriate papers for the use and authority of sleeping medications and inappropriate equipment settings related to sleep devices are in charge of less market growth. Sensor-equipped arrangements are used for different purposes like checking sleep disorders and evaluating the excellence of sleep. An alternative important factor for the market of sleeping aids is the growing acceptance of vesture sensors and tracking devices. These devices distribute and record data regarding different physical conditions.
In addition, the sleep quality is also caught up due to more working hours, a hectic working environment, working different shifts, and tense situations, along with additional workload. There are various drugs offered by the market for the treatment of narcolepsy and insomnia, but these drugs have more side effects and are very hazardous. The adverse effects associated with sleep aid pills or medications are adverse allergic reactions, headaches, presentation difficulties, daytime memory problems, and extended drowsiness. All these issues or side effects pay to an increasing acceptance of OTC sleep aids pills which helps in falling asleep and gives a positive outcome on the demand for the market of sleeping aids.
Opportunities:
Changes in lifestyle and changes in sleeping patterns enhanced admission to services of healthcare, increasing customer wealth, and growing demand for worthy healthcare are driving the sleep aid providers. The increasing occurrence of sleep apnoea and insomnia has generated admirable chances for growth in the market of global sleep aids. Growing government funding and product sanctions for good treatment decisions and testing sleep apnoea are opening huge possibilities for manufacturers of sleep aid treatment products to fight against chronic sleep conditions and increase market share.
Sleep-inducing pillows and mattresses are more popular all over the world, and this has directly affected the development of the sleeping aids market. Increasing cases of the restless-leg syndrome and sleep-walking have also covered the arrival of huge revenues in the worldwide market of sleeping aids. Narcolepsy is also a sporadic condition that can be treated and controlled with the support of sleep aids. The market for global sleep aids will likely develop at a bright hope over the next years.
Challenges
The sleep market supports or aids are anticipated to appeal to huge revenues as new stakeholders or investors in the market show interest. The beginning of innovative medicines and sleep aid laboratories is expected to increase the demand in the market for worldwide sleep aids. Also, the sleeping aids market expanded together with developments in insomnia treatment.
Recent Developments
- Eisai Co., Ltd. declared that the USFDA permitted a new drug confirmation for its developed and domestic discovered DAYVIGOTM (Lemborexant) an antagonist of orexin receptor in December 2019. DAYVIGOTM was accepted for treating insomnia categorized by problems with sleep maintenance or sleep beginning in adults.
- Koninklijke Philips declared the inauguration of Dream Station Go in April 2017. It is the smallest and newest positive airline pressure (PAP) device intended to shorten transportability for patients with OSA.
- GSK declared the signing of the contract to influence genomic insights for the new medication development in July 2018.
Segments are covered in the report:
By Product
- Mattresses & Pillows
- Medications
- Prescription-based Drugs
- OTC drugs
- Herbal drugs
- Sleep Apnea Devices
- Positive Airway Pressure (PAP) Devices
- Facial Interfaces
- Oral Appliances
- Adaptive Servo-Ventilators (ASVs)
- Others
By Sleep-Disorder
- Insomnia
- Sleep Apnea
- Restless Legs Syndrome
- Narcolepsy
- Sleep Walking
- Other Sleep Disorders
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa
Key Points of Sleep Aids Market
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Sleep Aids Market
5.1. COVID-19 Landscape: Sleep Aids Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Sleep Aids Market, By Product
8.1. Sleep Aids Market, by Product, 2022-2030
8.1.1. Mattresses & Pillows
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Medications
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Sleep Apnea Devices
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Sleep Aids Market, By Sleep-Disorder
9.1. Sleep Aids Market, by Sleep-Disorder, 2022-2030
9.1.1. Insomnia
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Sleep Apnea
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Restless Legs Syndrome
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Narcolepsy
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Sleep Walking
9.1.5.1. Market Revenue and Forecast (2017-2030)
9.1.6. Other Sleep Disorders
9.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Sleep Aids Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Product (2017-2030)
10.1.2. Market Revenue and Forecast, by Sleep-Disorder (2017-2030)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Product (2017-2030)
10.1.3.2. Market Revenue and Forecast, by Sleep-Disorder (2017-2030)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.1.4.2. Market Revenue and Forecast, by Sleep-Disorder (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.2. Market Revenue and Forecast, by Sleep-Disorder (2017-2030)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.3.2. Market Revenue and Forecast, by Sleep-Disorder (2017-2030)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.4.2. Market Revenue and Forecast, by Sleep-Disorder (2017-2030)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.5.2. Market Revenue and Forecast, by Sleep-Disorder (2017-2030)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.6.2. Market Revenue and Forecast, by Sleep-Disorder (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.2. Market Revenue and Forecast, by Sleep-Disorder (2017-2030)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.3.2. Market Revenue and Forecast, by Sleep-Disorder (2017-2030)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.4.2. Market Revenue and Forecast, by Sleep-Disorder (2017-2030)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.5.2. Market Revenue and Forecast, by Sleep-Disorder (2017-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.6.2. Market Revenue and Forecast, by Sleep-Disorder (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.2. Market Revenue and Forecast, by Sleep-Disorder (2017-2030)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.3.2. Market Revenue and Forecast, by Sleep-Disorder (2017-2030)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.4.2. Market Revenue and Forecast, by Sleep-Disorder (2017-2030)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.5.2. Market Revenue and Forecast, by Sleep-Disorder (2017-2030)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.6.2. Market Revenue and Forecast, by Sleep-Disorder (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.5.2. Market Revenue and Forecast, by Sleep-Disorder (2017-2030)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Product (2017-2030)
10.5.3.2. Market Revenue and Forecast, by Sleep-Disorder (2017-2030)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.5.4.2. Market Revenue and Forecast, by Sleep-Disorder (2017-2030)
Chapter 11. Company Profiles
11.1. Acelity L.P. Inc. (Kinetic Concepts, Inc.)
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. AstraZeneca Plc
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Biodiem
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Cadwell Industries Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Compumedics Limited
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. CSL Limited
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Drive
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Drive DeVilbiss Healthcare Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Eisai Co., Ltd.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Emergent Biosolutions
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Immediate Delivery Available | Buy this Premium Research Report@ https://www.precedenceresearch.com/checkout/1978
